Cardiovascular risk and subclinical cardiovascular disease in polycystic ovary syndrome

Frontiers of Hormone Research

Volumn 40, Issue , 2013, Pages 64-82

  Bajuk Studen, Katica ^a   Jensterle Sever, Mojca ^a   Pfeifer, Marija ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ARGININE; ATENOLOL; C REACTIVE PROTEIN; CYPROTERONE ACETATE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DROSPIRENONE; ENDOTHELIN 1; ETHINYLESTRADIOL; EXENDIN 4; FATTY ACID; GLUCAGON LIKE PEPTIDE 1; HOMOCYSTEINE; HYDROGEN PEROXIDE; LIPOPROTEIN; METFORMIN; METOPROLOL; MITOGEN ACTIVATED PROTEIN KINASE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; PLASMINOGEN ACTIVATOR INHIBITOR 1; REACTIVE OXYGEN METABOLITE; ROSIGLITAZONE; SPIRONOLACTONE; TROGLITAZONE; TYROSINE; UNINDEXED DRUG; VASCULOTROPIN; 2,4 THIAZOLIDINEDIONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INCRETIN; ANDROSTANE DERIVATIVE;

ANGIOCARDIOGRAPHY; ARTERIAL STIFFNESS; ARTERIAL WALL THICKNESS; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTICLE; ATHEROSCLEROSIS; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CAROTID ATHEROSCLEROSIS; CELL PROLIFERATION; CHRONIC INFLAMMATION; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY CALCIFICATION; CORRELATION ANALYSIS; DIET; DRUG MEGADOSE; DYSLIPIDEMIA; ECHOGRAPHY; ELECTRON BEAM TOMOGRAPHY; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; EVENT FREE SURVIVAL; EXERCISE; GENETIC HETEROGENEITY; HEART CATHETERIZATION; HEART INFARCTION; HIRSUTISM; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPERTENSION; HYPOTENSION; INSULIN RESISTANCE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; MENSTRUAL IRREGULARITY; META ANALYSIS (TOPIC); NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; POSITIVE END EXPIRATORY PRESSURE; POSTMENOPAUSE; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SLEEP DISORDERED BREATHING; SMOOTH MUSCLE FIBER; STATISTICAL SIGNIFICANCE; THORAX PAIN; WAIST HIP RATIO; WEIGHT GAIN; WEIGHT REDUCTION; ATHEROGENESIS; BODY WEIGHT; CLINICAL FEATURE; INCIDENCE; METABOLIC DISORDER; MORBIDITY; RISK FACTOR; ADOLESCENT; ADULT; CARDIOVASCULAR DISEASES; COMPLICATION; CORONARY ARTERY DISEASE; FEMALE; LIFESTYLE; MIDDLE AGED; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; POLYCYSTIC OVARY SYNDROME; SLEEP APNEA, OBSTRUCTIVE;

ADOLESCENT; ADULT; ANDROSTENES; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; CAROTID INTIMA-MEDIA THICKNESS; CORONARY ARTERY DISEASE; FEMALE; HUMANS; HYPERTENSION; INCRETINS; INSULIN RESISTANCE; LIFE STYLE; METFORMIN; MIDDLE AGED; OBESITY; POLYCYSTIC OVARY SYNDROME; POSTMENOPAUSE; RENIN-ANGIOTENSIN SYSTEM; RISK FACTORS; SLEEP APNEA, OBSTRUCTIVE; THIAZOLIDINEDIONES; VASCULAR STIFFNESS; WEIGHT REDUCTION PROGRAMS;

EID: 84870272357     PISSN: 03013073     EISSN: 16623762     Source Type: Book Series    
DOI: 10.1159/000341838     Document Type: Article

References (40)

1. Birdsall MA, Farquhar CM, White HD: Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. Ann Intern Med 1997;126:32.
2. Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC, Speizer FE, Manson JE: Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002; 87:2013.
3. Shaw LJ, Bairey Merz CN, Azziz R, et al: Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health-National Heart, Lung, and Blood Institute Sponsored Women's Ischemia Syndrome Evaluation. J Clin Endocrinol Metab 2008;93:1276.
4. Krentz AJ, von Muhlen D, Barrett-Connor E: Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease. Menopause 2007;14:284.
5. Azevedo GD, Duarte JM, Souza MO, Costa-E-Silva TD, Soares EM, Maranhao TM: Menstrual cycle irregularity as a marker of cardiovascular risk factors at postmenopausal years. Arq Bras Endocrinol Metabol 2006;50:876.
6. Wild S, Pierpoint T, McKeigue P, Jacobs H: Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol (Oxf) 2000; 52:595.
7. Elting MW, Korsen TJ, Bezemer PD, Schoemaker J: Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod 2001;16:556.
8. Wang ET, Cirillo PM, Vittinghoff E, Bibbins-Domingo K, Cohn BA, Cedars MI: Menstrual irregularity and cardiovascular mortality. J Clin Endocrinol Metab 2011;96:E114.
9. de Groot PCM, Dekkers OM, Romijn JA, Dieben SWM, Helmerhorst FM: PCOS, coronary heart disease, stroke and the influence of obesity: a systematic review and meta-analysis. Hum Reprod Update 2011;17:495.
10. Lambrinoudaki I: Cardiovascular risk in postmenopausal women with the polycystic ovary syndrome. Maturitas 2011;68:13.
11. Ouyang P, Vaidya D, Dobs A, Golden SH, Szklo M, Heckbert SR, Kopp P, Gapstur SM: Sex hormone levels and subclinical atherosclerosis in postmenopausal women: the multi-ethnic study of atherosclerosis. Atherosclerosis 2009;204:255.
12. Toulis KA, Goulis DG, Mintziori G, Kintiraki E, Eukarpidis E, Mouratoglou SA, Pavlaki A, Stergianos S, Poulasouchidou M, Tzellos TG, Makedos A, Chourdakis M, Tarlatzis BC: Meta-analysis of cardiovascular disease risk markers in women with polycystic ovary syndrome. Hum Reprod Update 2011;17:741.
13. Wild RA, Carmina E, Diamanti-Kandarakis E, Dokras A, Escobar-Morreale HF, Futterweit W, Lobo R, Norman RJ, Talbott E, Dumesic DA: Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society. J Clin Endocrinol Metab 2010; 95:2038.
14. Kelly CJ, Speirs A, Gould GW, Petrie JR, Lyall H, Connell JM: Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2002;87:742.
15. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I: Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. J Clin Endocrinol Metab 2001;86:4666.
16. Bentley-Lewis R, Seely E, Dunaif A: Ovarian hypertension: polycystic ovary syndrome. Endocrinol Metab Clin North Am 2011;40:433.
17. Armanini D, Castello R, Scaroni C, Bonanni G, Faccini G, Pellati D, Bertoldo A, Fiore C, Moghetti P: Treatment of polycystic ovary syndrome with spironolactone plus licorice. Eur J Obstet Gynecol Reprod Biol 2007;131:61.
18. Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, Laven JS: A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. J Clin Endocrinol Metab 2008;93:470.
19. Fauser BC, Tarlatzis BC, Rebar RW, et al: Consensus on women's health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRMSponsored 3rd PCOS Consensus Workshop Group. Fertil Steril 2012;97:28.
20. Rossi G, Boscaro M, Ronconi V, Funder JW: Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab 2005;16:104.
21. Cascella T, Palomba S, Tauchmanova L, Manguso F, Di Biase S, Labella D, Giallauria F, Vigorito C, Colao A, Lombardi G, Orio F: Serum aldosterone concentration and cardiovascular risk in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2006;91:439522.
22. Bajuk-Studen K, Šebeštjen M, Pfeifer M, Preželj J: Influence of spironolactone treatment on endothelial function in non-obese women with polycystic ovary syndrome. Eur J Endocrinol 2011;164:389.
23. Davies JI, Band M, Morris A, Struthers AD: Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia 2004;47:1687.
24. Nitsche K, Ehrmann DA: Obstructive sleep apnea and metabolic dysfunction in polycystic ovary syndrome. Best Pract Res Clin Endocrinol Metab 2010;24:717.
25. Tasali E, Chapotot F, Leproult L, Whitmore H, Ehrmann DA: Treatment of obstructive sleep apnea improves cardiometabolic function in young obese women with polycystic ovary syndrome. J Clin Endocrinol Metab 2011;96:365.
26. Deanfield JE, Halcox JP, Rabelink TJ: Endothelial function and dysfunction. Circulation 2007;115: 1285.
27. Kim J, Montagnani M, Kon Koh K, Quon MJ: Reciprocal relationships between insulin resistance and endothelial dysfunction. Molecular and pathophysiological mechanisms. Circulation 2006;113: 1888.
28. Paradisi G, Steinberg HO, Hempfling A, Cronin J, Hook G, Shepard MK, Baron AD: Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001;103:1410.
29. Kravariti M, Naka KK, Kalantaridou SN, Kazakos N, Katsouras CS, Makrigiannakis A, Paraskevaidis EA, Chrousos GP, Tsatsoulis A, Michalis LK: Predictors of endothelial dysfunction in young women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90:5088.
30. Moran LJ, Noakes M, Clifton PM, Tomlinson L, Galletly C, Norman RJ: Dietary composition in restoring reproductive and metabolic physiology in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88:812.
31. Mosca L: Guidelines for prevention of cardiovascular disease in women: a summary of recommendations. Prev Cardiol 2007;10(suppl 4):19.
32. Diamanti-Kandarakis E, Alexandraki K, Protogerou A, Piperi C, Papamichael C, Aessopos A, Lekakis J, Mavrikakis M: Metformin administration improves endothelial function in women with polycystic ovary syndrome. Eur J Endocrinol 2005;152:749.
33. Orio F Jr, Palomba S, Cascella T, De Simone B, Manguso F, Savastano S, Russo T, Tolino A, Zullo F, Lombardi G, Azziz R, Colao A: Improvement in endothelial structure and function after metformin treatment in young normal-weight women with polycystic ovary syndrome: results of a 6-month study. J Clin Endocrinol Metab 2005;90:6072.
34. Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O'Keefe M, Ghazzi MN, PCOS/Troglitazone Study Group: Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 2001; 86:1626.
35. Tarkun I, Cetinarslan B, Turemen E, Sahin T, Canturk Z, Komsuoglu B: Effect of rosiglitazone on insulin resistance, C-reactive protein and endothelial function in non-obese young women with polycystic ovary syndrome. Eur J Endocrinol 2005; 153:115.
36. Jensterle M, Šebeštjen M, Janež A, Preželj J, Kocjan T, Keber I, Pfeifer M: Improvement of endothelial function with metformin and rosiglitazone treatment in women with polycystic ovary syndrome. Eur J Endocrinol 2008;159:399.
37. Mancini F, Cianciosi A, Persico N, Facchinetti F, Busacchi P, Battaglia C: Drospirenone and cardiovascular risk in lean and obese polycystic ovary syndrome patients: a pilot study. Am J Obstet Gynecol 2010;202:169.
38. Sathyapalan T, Atkin S: Review topic on mechanisms in endocrinology - recent advances in the cardiovascular aspects of polycystic ovary syndrome. Eur J Endocrinol 2012;166:575.
39. Pontikis C, Yavropoulou MP, Toulis KA, Kotsa K, Kazakos K, Papazisi A, Gotzamani-Psarakou A, Yovos JG: The incretin effect and secretion in obese and lean women with polycystic ovary syndrome: a pilot study. J Womens Health (Larchmt) 2011;20: 971.
40. Elkind-Hirsch K, Marrioneaux O, Bhushan M, Vernor D, Bhushan R: Comparison of single and combined treatment with exenatide and metformin on menstrual cyclicity in overweight women with polycystic ovary syndrome. J Clin Endocrinol Metab 2008;93:2670.